Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[99mTc]Tc-DB8 Imaging in Primary Breast Cancer
NCT07275463Phase 2Enrolling by invitation
- Sponsor
- Tomsk National Research Medical Centre of the Russian Academy of Sciences
- Start
- Oct 2025
- Primary completion
- Dec 2026
- Modality
- Alpha Emitters, Beta Emitters
- Countries
- 1
01
Overview
Phase 2, open-label trial of [99mTc]Tc-DB8 in breast cancer (2 arms), sponsored by Tomsk National Research Medical Centre of the Russian Academy of Sciences. Primary endpoints: [99mTc]Tc-DB8 uptake in primary breast tumor at 2 hours, [99mTc]Tc-DB8 background uptake value at 2 hours and 1 more. Started Oct 2025; status: enrolling by invitation.
02
Drugs
[99mTc]Tc-DB8
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07275463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07275463.